Cerus Co. (NASDAQ:CERS) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Cerus Co. (NASDAQ:CERS) by 0.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,754,540 shares of the biotechnology company’s stock after purchasing an additional 8,707 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Cerus were worth $3,053,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CERS. Assenagon Asset Management S.A. grew its stake in shares of Cerus by 6.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,257,571 shares of the biotechnology company’s stock valued at $2,188,000 after buying an additional 71,007 shares during the period. Hood River Capital Management LLC increased its stake in Cerus by 390.4% during the second quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company’s stock worth $2,587,000 after acquiring an additional 1,170,060 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Cerus in the third quarter valued at $353,000. The Manufacturers Life Insurance Company lifted its stake in shares of Cerus by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 7,209 shares during the last quarter. Finally, Creative Planning grew its holdings in shares of Cerus by 51.3% during the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,411 shares during the period. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Cerus Stock Performance

NASDAQ:CERS opened at $1.71 on Friday. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.59. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The company has a 50 day moving average price of $1.75 and a 200 day moving average price of $1.91. The stock has a market capitalization of $317.57 million, a P/E ratio of -15.55 and a beta of 1.24.

Analyst Ratings Changes

Separately, Stifel Nicolaus reduced their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.